273 related articles for article (PubMed ID: 29956186)
41. Differentiation of feline immunodeficiency virus vaccination, infection, or vaccination and infection in cats.
Levy JK; Crawford PC; Kusuhara H; Motokawa K; Gemma T; Watanabe R; Arai S; Bienzle D; Hohdatsu T
J Vet Intern Med; 2008; 22(2):330-4. PubMed ID: 18371028
[TBL] [Abstract][Full Text] [Related]
42. Neutralising antibody response in domestic cats immunised with a commercial feline immunodeficiency virus (FIV) vaccine.
Bęczkowski PM; Harris M; Techakriengkrai N; Beatty JA; Willett BJ; Hosie MJ
Vaccine; 2015 Feb; 33(8):977-84. PubMed ID: 25613718
[TBL] [Abstract][Full Text] [Related]
43. Feline cytokine ELISPOT: issues in assay development.
Nordone SK; Stevens R; LaVoy AS; Dean GA
Methods Mol Biol; 2005; 302():167-78. PubMed ID: 15937351
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of a feline immunodeficiency virus vaccine.
Huang C; Conlee D; Loop J; Champ D; Gill M; Chu HJ
Anim Health Res Rev; 2004 Dec; 5(2):295-300. PubMed ID: 15984343
[TBL] [Abstract][Full Text] [Related]
45. Mucosal infection and vaccination against feline immunodeficiency virus.
Stokes CR; Finerty S; Gruffydd-Jones TJ; Sturgess CP; Harbour DA
J Biotechnol; 1999 Aug; 73(2-3):213-21. PubMed ID: 10486930
[TBL] [Abstract][Full Text] [Related]
46. Duration of antibody response following vaccination against feline immunodeficiency virus.
Westman ME; Malik R; Hall E; Harris M; Hosie MJ; Norris JM
J Feline Med Surg; 2017 Oct; 19(10):1055-1064. PubMed ID: 27770018
[TBL] [Abstract][Full Text] [Related]
47. 16alpha-Bromo-epiandrosterone therapy modulates experimental feline immunodeficiency virus viremia: initial enhancement leading to long-term suppression.
Pedersen NC; North TW; Rigg R; Reading C; Higgins J; Leutenegger C; Henderson GL
Vet Immunol Immunopathol; 2003 Aug; 94(3-4):133-48. PubMed ID: 12909410
[TBL] [Abstract][Full Text] [Related]
48. Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects.
Sanou MP; Roff SR; Mennella A; Sleasman JW; Rathore MH; Yamamoto JK; Levy JA
J Virol; 2013 Sep; 87(18):10004-15. PubMed ID: 23824804
[TBL] [Abstract][Full Text] [Related]
49. Passive antibody protection of cats against feline immunodeficiency virus infection.
Hohdatsu T; Pu R; Torres BA; Trujillo S; Gardner MB; Yamamoto JK
J Virol; 1993 Apr; 67(4):2344-8. PubMed ID: 8383246
[TBL] [Abstract][Full Text] [Related]
50. CD8+ T cells from feline immunodeficiency virus (FIV) infected cats suppress exogenous FIV replication of their peripheral blood mononuclear cells in vitro.
Hohdatsu T; Sasagawa T; Yamazaki A; Motokawa K; Kusuhara H; Kaneshima T; Koyama H
Arch Virol; 2002 Aug; 147(8):1517-29. PubMed ID: 12181672
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of vaccination strategies against infection with feline immunodeficiency virus (FIV) based on recombinant viral vectors expressing FIV Rev and OrfA.
Huisman W; Schrauwen EJ; Tijhaar E; Süzer Y; Pas SD; van Amerongen G; Sutter G; Rimmelzwaan GF; Osterhaus AD
Vet Immunol Immunopathol; 2008 Dec; 126(3-4):332-8. PubMed ID: 18952300
[TBL] [Abstract][Full Text] [Related]
52. Oral immunization with recombinant listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus.
Stevens R; Howard KE; Nordone S; Burkhard M; Dean GA
J Virol; 2004 Aug; 78(15):8210-8. PubMed ID: 15254192
[TBL] [Abstract][Full Text] [Related]
53. Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus.
Hosie MJ; Dunsford T; Klein D; Willett BJ; Cannon C; Osborne R; Macdonald J; Spibey N; Mackay N; Jarrett O; Neil JC
J Virol; 2000 Oct; 74(20):9403-11. PubMed ID: 11000209
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of feline monocyte-derived dendritic cells loaded with internally inactivated virus as a vaccine against feline immunodeficiency virus.
Freer G; Matteucci D; Mazzetti P; Tarabella F; Catalucci V; Ricci E; Merico A; Bozzacco L; Pistello M; Bendinelli M
Clin Vaccine Immunol; 2008 Mar; 15(3):452-9. PubMed ID: 18216184
[TBL] [Abstract][Full Text] [Related]
55. Effects of incidental infections and immune activation on disease progression in experimentally feline immunodeficiency virus-infected cats.
Reubel GH; Dean GA; George JW; Barlough JE; Pedersen NC
J Acquir Immune Defic Syndr (1988); 1994 Oct; 7(10):1003-15. PubMed ID: 7916048
[TBL] [Abstract][Full Text] [Related]
56. Accelerated viraemia in cats vaccinated with fixed autologous FIV-infected cells.
Karlas JA; Siebelink KH; v Peer MA; Huisman W; Rimmelzwaan GF; Osterhaus AD
Vet Immunol Immunopathol; 1998 Oct; 65(2-4):353-65. PubMed ID: 9839884
[TBL] [Abstract][Full Text] [Related]
57. Vaccination with a feline immunodeficiency virus multiepitopic peptide induces cell-mediated and humoral immune responses in cats, but does not confer protection.
Flynn JN; Cannon CA; Neil JC; Jarrett O
J Virol; 1997 Oct; 71(10):7586-92. PubMed ID: 9311839
[TBL] [Abstract][Full Text] [Related]
58. Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus.
Pistello M; Bonci F; Zabogli E; Conti F; Freer G; Maggi F; Stevenson M; Bendinelli M
J Virol; 2010 Apr; 84(8):3845-56. PubMed ID: 20130057
[TBL] [Abstract][Full Text] [Related]
59. Vaccination of cats experimentally infected with feline immunodeficiency virus, using a recombinant feline leukemia virus vaccine.
Lehmann R; Franchini M; Aubert A; Wolfensberger C; Cronier J; Lutz H
J Am Vet Med Assoc; 1991 Nov; 199(10):1446-52. PubMed ID: 1666101
[TBL] [Abstract][Full Text] [Related]
60. Assessment of CD4+ and CD8+ IFN-gamma producing cells by ELISPOT in naïve and FIV-infected cats.
Sirriyah J; Dean GA; LaVoy A; Burkhard MJ
Vet Immunol Immunopathol; 2004 Nov; 102(1-2):77-84. PubMed ID: 15451617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
